Cargando…

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA

Two randomized, placebo-controlled studies evaluated the pulmonary function safety of onabotulinumtoxinA (onabotA) for treatment of upper and/or lower limb spasticity. Patients with stable baseline respiratory status received one or two treatments with placebo, 240 U, or 360 U of onabotA. Pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayyoub, Ziyad, Brashear, Allison, Banach, Marta, Schoene, Robert, Stringer, William, Boodhoo, Terry, Yushmanova, Irina, Dimitrova, Rozalina, Brin, Mitchell F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589715/
https://www.ncbi.nlm.nih.gov/pubmed/33086749
http://dx.doi.org/10.3390/toxins12100661
_version_ 1783600642329149440
author Ayyoub, Ziyad
Brashear, Allison
Banach, Marta
Schoene, Robert
Stringer, William
Boodhoo, Terry
Yushmanova, Irina
Dimitrova, Rozalina
Brin, Mitchell F.
author_facet Ayyoub, Ziyad
Brashear, Allison
Banach, Marta
Schoene, Robert
Stringer, William
Boodhoo, Terry
Yushmanova, Irina
Dimitrova, Rozalina
Brin, Mitchell F.
author_sort Ayyoub, Ziyad
collection PubMed
description Two randomized, placebo-controlled studies evaluated the pulmonary function safety of onabotulinumtoxinA (onabotA) for treatment of upper and/or lower limb spasticity. Patients with stable baseline respiratory status received one or two treatments with placebo, 240 U, or 360 U of onabotA. Pulmonary function tests, adverse events, and efficacy were measured at least every 6 weeks for 18 weeks (Study 1) or 30 weeks (Study 2). Study 1 enrolled 109 patients (n = 36–37/group) and Study 2 enrolled 155 patients (n = 48–54/group). Mean baseline forced vital capacity (FVC) was 76–78% of predicted per group in Study 1 and 71% of predicted per group in Study 2. In Study 1, change from baseline FVC values were significantly (p < 0.05) decreased vs. placebo at weeks 3 (240 U −57 mL vs. placebo +110 mL) and 12 (360 U −6 mL vs. +167 mL placebo). In Study 2, change from baseline FVC values were significantly decreased in the 360 U group vs. placebo at weeks 6 (−78 mL vs. +49 mL placebo), 13 (−60 mL vs. +119 mL placebo), 18 (−128 mL vs. +80 mL placebo), and 24 (−82 mL vs. +149 mL placebo). Individual pulmonary function-related adverse events were not correlated with PFT decreases. The most frequent pulmonary-related adverse events were nasopharyngitis (Study 1) and upper respiratory tract infection (Study 2). Ashworth scores were significantly improved at multiple time points in both studies. Injection of onabotA for spasticity in patients with decreased pulmonary function, at single and repeated doses of up to 360 U, was associated with small but statistically significant decreases in FVC or forced expiratory volume 1 s (FEV1) (>12% and 200 mL) that were subclinical and not correlated with any adverse clinical pulmonary events.
format Online
Article
Text
id pubmed-7589715
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75897152020-10-29 Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA Ayyoub, Ziyad Brashear, Allison Banach, Marta Schoene, Robert Stringer, William Boodhoo, Terry Yushmanova, Irina Dimitrova, Rozalina Brin, Mitchell F. Toxins (Basel) Article Two randomized, placebo-controlled studies evaluated the pulmonary function safety of onabotulinumtoxinA (onabotA) for treatment of upper and/or lower limb spasticity. Patients with stable baseline respiratory status received one or two treatments with placebo, 240 U, or 360 U of onabotA. Pulmonary function tests, adverse events, and efficacy were measured at least every 6 weeks for 18 weeks (Study 1) or 30 weeks (Study 2). Study 1 enrolled 109 patients (n = 36–37/group) and Study 2 enrolled 155 patients (n = 48–54/group). Mean baseline forced vital capacity (FVC) was 76–78% of predicted per group in Study 1 and 71% of predicted per group in Study 2. In Study 1, change from baseline FVC values were significantly (p < 0.05) decreased vs. placebo at weeks 3 (240 U −57 mL vs. placebo +110 mL) and 12 (360 U −6 mL vs. +167 mL placebo). In Study 2, change from baseline FVC values were significantly decreased in the 360 U group vs. placebo at weeks 6 (−78 mL vs. +49 mL placebo), 13 (−60 mL vs. +119 mL placebo), 18 (−128 mL vs. +80 mL placebo), and 24 (−82 mL vs. +149 mL placebo). Individual pulmonary function-related adverse events were not correlated with PFT decreases. The most frequent pulmonary-related adverse events were nasopharyngitis (Study 1) and upper respiratory tract infection (Study 2). Ashworth scores were significantly improved at multiple time points in both studies. Injection of onabotA for spasticity in patients with decreased pulmonary function, at single and repeated doses of up to 360 U, was associated with small but statistically significant decreases in FVC or forced expiratory volume 1 s (FEV1) (>12% and 200 mL) that were subclinical and not correlated with any adverse clinical pulmonary events. MDPI 2020-10-19 /pmc/articles/PMC7589715/ /pubmed/33086749 http://dx.doi.org/10.3390/toxins12100661 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ayyoub, Ziyad
Brashear, Allison
Banach, Marta
Schoene, Robert
Stringer, William
Boodhoo, Terry
Yushmanova, Irina
Dimitrova, Rozalina
Brin, Mitchell F.
Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
title Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
title_full Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
title_fullStr Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
title_full_unstemmed Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
title_short Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
title_sort safety and stability of pulmonary function in patients with decreased respiratory function treated for spasticity with onabotulinumtoxina
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589715/
https://www.ncbi.nlm.nih.gov/pubmed/33086749
http://dx.doi.org/10.3390/toxins12100661
work_keys_str_mv AT ayyoubziyad safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT brashearallison safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT banachmarta safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT schoenerobert safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT stringerwilliam safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT boodhooterry safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT yushmanovairina safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT dimitrovarozalina safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina
AT brinmitchellf safetyandstabilityofpulmonaryfunctioninpatientswithdecreasedrespiratoryfunctiontreatedforspasticitywithonabotulinumtoxina